513 material Form 8-K filings that 427 companies we cover made with the SEC in November 2024, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
Arrowhead Pharmaceuticals reported a fiscal 2024 net loss attributable to the company of $599.5 million, or $5.00 per diluted share, for the year ended September 30, 2024, compared with a loss of $205.3 million, or $1.92 per share, a year earlier. Revenue fell to $3.6 million from $240.7 million, while research and development expense rose to $505.9 million from $353.2 million. The company said its recent Sarepta licensing deal and Sixth Street credit facility, both announced in the filing period, extend its cash runway into 2028.
Revenue was $3.6 million in fiscal 2024 versus $240.7 million in fiscal 2023.
Diluted net loss per share was $5.00 versus $1.92 a year earlier.
Research and development expense was $505.9 million versus $353.2 million.
Sarepta agreement provides $825 million upon closing, including a $325 million equity investment; Sixth Street facility is $500 million, with $400 million funded at close.
HP reported fiscal 2024 results for the year ended October 31, 2024, with net revenue of $53.6 billion, down 0.3%, and GAAP diluted EPS of $2.81, down from $3.26 a year earlier but above its previously provided outlook. Fourth-quarter net revenue rose 1.7% to $14.1 billion, and the board raised the quarterly dividend 5% to $0.2894 per share. HP's fiscal 2025 non-GAAP diluted EPS outlook is $3.45 to $3.75, compared with $3.38 in fiscal 2024.
Fiscal 2024 net revenue was $53.6 billion, down 0.3%; GAAP diluted EPS was $2.81 versus $3.26 in fiscal 2023
Fourth-quarter net revenue was $14.1 billion, up 1.7%; non-GAAP diluted EPS was $0.93 versus $0.90
Quarterly dividend increased 5% to $0.2894 per share, payable January 2, 2025 to holders of record as of December 11, 2024
Fiscal 2025 outlook: non-GAAP diluted EPS of $3.45 to $3.75 and free cash flow of $3.2 billion to $3.6 billion
For the quarter ended October 31, 2024, J.M. Smucker reported net sales of $2.3 billion, up 17% mainly due to the Hostess Brands acquisition, and adjusted earnings per share of $2.76, up 7%. The company posted a GAAP net loss of $0.23 per diluted share, versus earnings of $1.90 a year earlier, after a $260.8 million pre-tax loss on the Voortman business held for sale. The company raised its full-year fiscal 2025 adjusted earnings per share guidance to $9.70 to $10.10 from $9.60 to $10.00.
Net sales were $2.3 billion, up $332.6 million or 17%; excluding the acquisition, divestitures, and currency, net sales rose 2%.
GAAP net loss of $0.23 per diluted share, compared with $1.90 a year earlier, including a $260.8 million pre-tax loss on the Voortman business.
Adjusted earnings per share were $2.76, up 7%; free cash flow was $317.2 million versus $28.2 million a year earlier.
Fiscal 2025 adjusted earnings per share guidance raised to $9.70 to $10.10 from $9.60 to $10.00; net sales growth guidance unchanged at 8.5% to 9.5%.
Burlington reported third-quarter fiscal 2024 total sales up 11% to $2,526 million and net income of $91 million, or $1.40 per diluted share, versus $49 million, or $0.75, a year earlier. The company raised its full-year fiscal 2024 adjusted EPS guidance to $7.76 to $7.96, but comparable store sales grew only 1%, and its fourth-quarter guidance calls for a lower adjusted EBIT margin.
Q3 total sales rose 11% to $2,526 million; comparable store sales rose 1%, which management attributed to warmer weather from mid-September.
Q3 net income was $91 million, or $1.40 per diluted share; adjusted EPS rose 41% to $1.55.
Full-year fiscal 2024 adjusted EPS guidance was raised to $7.76 to $7.96.
Fourth-quarter guidance calls for comparable store sales growth of 0% to 2% and an adjusted EBIT margin decline of 50 to 80 basis points.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.